Bristol-Myers Squibb (BMY) has experienced various fluctuations in its stock value. The company's stock has both overperformed and underperformed compared to the market, with some suggesting it may rebound to its 2022 highs of $80. Multiple asset management firms have increased or decreased their holdings, indicating varying investor confidence levels. The company has been named in the Dow Jones Sustainability Index North America and has launched a $1.5 billion cost-cutting initiative after its quarterly loss. BMY has recently drawn investor attention after the US FDA's approval of their colorectal cancer therapy. Financial forecasts estimate a decline in Q1 earnings and the company has also seen a recent market cap drop of $5.7 billion, sparking concerns among institutional owners. Despite announcing plans to launch 16 new products by 2030, the company saw a quarterly loss following several multi-billion acquisitions. BMY's stock has also been mentioned as a potential long-term value investment, however, the company has also faced challenges to its drug price negotiation program.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Dec 2023 08:00:00 GMT to Sun, 30 Jun 2024 15:31:11 GMT -
Rating 2
- Innovation 6
- Information 7
- Rumor -5
